RNA Earnings Date 2026
Atrium Therapeutics, Inc. Common Stock earnings schedule and quarterly results
Next Earnings Date
TBD
Current Stock Price
$13.80
+0.22% today
Earnings Metrics
EPS (TTM)
$-2.89
P/E Ratio
-4.8
Revenue Growth
14.0%
Market Cap
$0.2B
Earnings History
| Quarter | EPS | Revenue | Net Income |
|---|---|---|---|
| Q4 2024 | $-2.89 | $0.01B | $-0.32B |
| Q4 2023 | $-2.91 | $0.01B | $-0.21B |
Trading Around RNA Earnings
Before Earnings
- Review analyst expectations and consensus estimates
- Check options implied volatility for expected move
- Consider historical earnings surprises
- Monitor pre-announcement guidance
After Earnings
- Compare actual results to estimates
- Listen to the earnings call for guidance
- Watch for analyst rating changes
- Monitor institutional buying/selling
Get Full RNA Analysis
DCF valuation, AI insights, and institutional ownership data
Frequently Asked Questions
When is RNA next earnings date?
RNA (Atrium Therapeutics, Inc. Common Stock) has not yet announced its next earnings date. Check back for updates on the upcoming earnings schedule.
What is RNA earnings per share (EPS)?
RNA's current earnings per share (EPS) is $-2.89. With a P/E ratio of -4.8, the market values each dollar of earnings at $-4.8.
How often does RNA report earnings?
Like most publicly traded US companies, RNA (Atrium Therapeutics, Inc. Common Stock) reports earnings quarterly, typically within 4-6 weeks after each fiscal quarter ends. The company holds an earnings call to discuss results with analysts.
What time does RNA report earnings?
RNA typically reports earnings either before market open (BMO) or after market close (AMC). The exact time is usually announced a few days before the earnings date. Check the investor relations page for specific timing.
How has RNA performed in recent earnings?
In the most recent quarter (Q4 2024), RNA reported EPS of $-2.89 on revenue of $0.01B.
What do analysts expect for RNA earnings?
Analyst expectations for RNA earnings can vary. The company has shown positive revenue growth of 14.0%. View the full analyst ratings page for detailed expectations.